The research team set out to answer a deceptively simple question: when prostate cancer cells stop responding to enzalutamide, what has actually changed inside them? Resistance is often described in terms of genetic mutations in the androgen receptor or amplification of the receptor gene itself, but these alterations explain only a fraction of clinical cases. Increasingly, cancer biologists have recognized that drug-tolerant cells frequently survive by adjusting their metabolism, the network of chemical reactions that converts nutrients into energy, building blocks and signaling molecules. Because metabolic rewiring is a physical requirement for survival rather than an optional accessory, it may represent a more universal and more druggable hallmark of resistance than any single mutation.

To capture that rewiring comprehensively, the investigators applied a multi-omic pipeline to paired models of enzalutamide-sensitive and enzalutamide-resistant prostate cancer cells. Transcriptomic sequencing revealed which genes were switched on or off; proteomic mass spectrometry quantified the enzymes actually present in the cells; and metabolomic profiling measured the small molecules, sugars, amino acids and lipids that flow through the metabolic network. The power of this approach lies in its convergence. A change in a single data type can be misleading, but when altered messenger RNA, altered protein and altered metabolite levels all point to the same pathway, the evidence becomes difficult to dismiss.

The analysis converged on several interconnected metabolic shifts. Resistant cells displayed a marked reorganization of lipid metabolism, upregulating pathways for fatty acid synthesis and elongation while also altering cholesterol handling. This makes biological sense for prostate cancer in particular, because the androgen receptor does more than respond to testosterone; it also regulates genes involved in lipid acquisition and synthesis, and membrane lipid composition influences receptor signaling at the cell surface. By boosting de novo lipogenesis, resistant cells appear to buffer themselves against the loss of androgen-driven lipid programs that enzalutamide imposes, effectively rebuilding a supply line the drug was designed to cut.

Energy metabolism showed equally telling changes. Profiling of central carbon metabolism indicated that resistant cells leaned more heavily on glycolysis and on glutamine-fueled anaplerosis, the process by which the amino acid glutamine tops up the tricarboxylic acid cycle with carbon. Mitochondrial oxidative phosphorylation was also reconfigured, with altered expression of electron transport chain components suggesting a shift in how resistant cells balance ATP production against the generation of biosynthetic precursors. These are not idle adjustments. Rapidly dividing tumor cells must simultaneously produce energy, reduce cellular building blocks and maintain antioxidant defenses, and the observed pattern is characteristic of cells that have traded metabolic efficiency for metabolic flexibility.

Crucially, the study did not stop at description. The researchers tested whether the metabolic alterations they detected could be exploited therapeutically. Inhibiting key enzymes in the upregulated lipid synthesis pathway reduced the viability of enzalutamide-resistant cells more severely than that of their drug-sensitive counterparts, indicating a genuine dependence rather than incidental correlation. Similar experiments targeting glutamine metabolism and mitochondrial respiration produced the same pattern of selective vulnerability. When metabolic inhibitors were combined with continued enzalutamide treatment, the effect was additive, and in some settings synergistic, meaning that the resistant cells could be resensitized to the drug they had learned to ignore.

The concept underlying these results is known as collateral vulnerability. When cancer cells evolve resistance to one pressure, the evolutionary path they take often creates new dependencies that did not exist before. A cell that ramps up fatty acid synthesis to survive androgen receptor blockade, for example, becomes exquisitely sensitive to inhibitors of that synthesis pathway. Because these dependencies are consequences of the resistance program itself, they are less likely to be bypassed by further tumor evolution without a significant fitness cost. This is the same logic that has made synthetic lethal strategies, such as PARP inhibition in DNA repair-deficient tumors, one of the most productive ideas in modern oncology, now extended into the metabolic arena.

The findings carry practical implications for the clinic. Enzalutamide resistance currently marks a transition point at which patients move toward chemotherapy, androgen biosynthesis inhibitors or, for those with suitable tumor biology, radioligand therapy. If metabolic vulnerabilities of the kind identified here can be confirmed in patient-derived models and ultimately in clinical trials, metabolic inhibitors could be layered onto existing regimens at the first sign of rising prostate-specific antigen during enzalutamide treatment, potentially delaying or preventing overt resistance. The study also raises the possibility of using metabolic imaging or circulating metabolite profiles as biomarkers, allowing clinicians to detect the metabolic shift before the tumor has fully escaped hormonal control.

Several caveats temper the enthusiasm. Cell line models, even well-characterized ones, capture only part of the complexity of human tumors, which contain stromal cells, immune infiltrates, variable oxygen and nutrient availability and extensive intratumoral heterogeneity. Metabolic phenotypes are notoriously context-dependent, shaped by the culture conditions in which cells are grown and by the specific evolutionary path each resistant line has taken. The authors’ use of multiple paired models and convergent multi-omic evidence strengthens their conclusions, but translating these dependencies into patients will require validation in organoids, xenografts and ultimately biopsy material from men whose disease has progressed on enzalutamide. Dose-limiting toxicities of metabolic inhibitors, particularly those affecting normal tissues with high metabolic flux, will also need careful management.

Nevertheless, the study represents a meaningful step toward a more complete picture of how prostate cancer defeats one of its most important therapies. By treating metabolism not as background housekeeping but as a central player in drug resistance, and by interrogating that metabolism with layers of molecular data rather than single measurements, the work provides both a mechanistic map and a practical target list. For the growing population of men living with castration-resistant prostate cancer, the hope is that the very adaptations tumors use to survive enzalutamide will become the handles by which the next generation of treatments pulls them back into vulnerability.

Subject of Research: Metabolic rewiring in enzalutamide-resistant prostate cancer identified through integrated transcriptomic, proteomic and metabolomic profiling

Article Title: Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer

Article References: Lee, O., Fidelito, G., Zhao, Q., Liu, B., Choi, H., Taylor, R. A., & Watt, M. J. (2026). Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03332-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03332-3

Keywords: prostate cancer, enzalutamide, drug resistance, multi-omics, metabolism, lipid metabolism, glutamine, androgen receptor, oxidative phosphorylation, collateral vulnerability, cancer therapeutics, Cell Death Discovery

The challenge in treating CRPC-NE lies in its aggressive nature and diminished dependence on androgen receptor signaling—a pathway conventional therapies target. Tumors frequently circumvent AR blockade by adopting neuroendocrine phenotypes, which no longer respond to AR inhibitors like enzalutamide, leading to poor clinical outcomes. Through sophisticated genetic manipulation of patient-derived organoid models, the research team demonstrated that ablating NSD2 reactivates AR expression and reinstitutes tumor vulnerability to enzalutamide, offering a novel method to overcome therapeutic resistance.

In an extensive series of experiments, NSD2 was inactivated via CRISPR-Cas9 mediated gene knockout in neuroendocrine prostate cancer organoids. Remarkably, this intervention reinstated AR protein levels that had previously been downregulated in CRPC-NE states. Employing dose–response assays, the investigators observed a significant reduction in organoid growth upon treatment with enzalutamide post-NSD2 targeting, with half-maximal inhibitory concentrations (IC50) plummeting below 3 micromolar. This quantitative shift underscored a dramatic re-sensitization of cancer cells to androgen deprivation therapies.

Extending these findings to in vivo models, the team employed subcutaneous grafting of both NSD2-deficient and control organoids into immunodeficient NOD/SCID mice. Upon reaching a critical tumor size, animals were treated with enzalutamide or vehicle control. Tumors lacking NSD2 exhibited significantly impaired growth under androgen blockade, while controls continued to proliferate unabated. Histological examination revealed a profound phenotypic switch; loss of neuroendocrine markers coupled with decreased proliferation indices such as Ki67 and resurgence of adenocarcinoma characteristics highlighted epigenetic reversion towards a more canonical prostate cancer state.

Parallel experiments utilizing human-derived MSKPCa10 organoids substantiated the translational relevance of these findings. NSD2 knockout in these human cells similarly restored responsiveness to enzalutamide both in vitro and in xenograft models, suggesting a conserved mechanism linking NSD2 activity to drug resistance across species. This critical validation establishes NSD2 as a viable target for clinical intervention in therapy-refractory prostate cancers.

Mechanistic insights at the molecular level revealed that NSD2 depletion triggers a global reprogramming of androgen receptor signaling. The expression of classical AR target genes showed robust enrichment post-NSD2 targeting, an effect confirmed at single-cell resolution. Notably, NSD2-deficient organoids manifested a proliferative response to the AR agonist dihydrotestosterone (DHT), which was absent in controls—indicating a restoration of functional AR signaling capable of modulating tumor cell growth.

This study situates NSD2 as a central epigenetic effector that governs phenotypic plasticity in prostate cancer, facilitating the shift from AR-dependent adenocarcinoma to neuroendocrine phenotypes upon which standard therapies fail. By reversing this epigenetic switch, NSD2 inhibition reinstates the canonical AR transcriptional program, reversing resistance and sensitizing tumors to enzalutamide. These findings unlock new paths for targeted epigenetic therapy, potentially combining NSD2 inhibitors with existing AR antagonists to overcome resistance mechanisms.

Furthermore, the work highlights the utility of patient-derived organoids as powerful preclinical platforms enabling precise genetic editing and pharmacological testing. This approach allows real-time evaluation of molecular dependencies within heterogeneous cancer cell populations, accelerating the discovery of context-specific vulnerabilities. The successful translation of organoid-based results into in vivo murine models strengthens the potential for rapid clinical application.

Overall, this paradigm-changing research advances our understanding of molecular determinants underpinning prostate cancer evolution and therapy resistance. It underscores the intricate interplay between epigenetic modifiers and hormonal signaling pathways, offering hope for more durable and effective interventions against metastatic prostate cancer. With further development, NSD2 targeting could usher in a new era of precision epigenetic therapies complementing androgen receptor blockade.

The promising results prompt urgent exploration into the development of selective NSD2 inhibitors suitable for clinical use. Future investigations will be crucial to unravel potential off-target effects, establish optimal dosing regimens, and assess therapeutic windows when combined with enzalutamide. Given the dire prognosis associated with CRPC-NE, this line of research may significantly extend survival and improve quality of life for affected patients.

In light of these discoveries, integrating epigenetic modulation strategies into standard prostate cancer treatment algorithms appears an auspicious direction. The elucidation of resistance reversal mechanisms by NSD2 loss provides a conceptual blueprint for tackling the heterogeneity and adaptability that have so far confounded durable responses in late-stage disease. As research progresses, the prospect of overcoming the deadliest phenotypes of prostate cancer moves closer to reality.

These breakthroughs also raise compelling questions about the broader role of epigenetic regulators in cancer plasticity and drug resistance beyond prostate cancer. By exploiting similar vulnerabilities in other malignancies exhibiting lineage plasticity, targeted NSD2 inhibition or analogous epigenetic reprogramming might enhance responsiveness to a variety of existing therapies. This study therefore opens avenues of translational potential across oncology.

In conclusion, the identification of NSD2 as a pivotal regulator of therapeutic plasticity and resistance in neuroendocrine prostate cancer represents a milestone in cancer epigenetics and precision medicine. The restoration of enzalutamide sensitivity via NSD2 targeting reveals actionable vulnerabilities that can be leveraged to design revolutionary treatment combinations. This paradigm shift affords renewed hope for patients battling drug-resistant prostate cancer and exemplifies the power of integrating genetic and epigenetic insights to surmount clinical challenges.

Subject of Research: Epigenetic regulation and therapeutic resistance in neuroendocrine prostate cancer

Article Title: NSD2 targeting reverses plasticity and drug resistance in prostate cancer

Article References:
Li, J.J., Vasciaveo, A., Karagiannis, D. et al. NSD2 targeting reverses plasticity and drug resistance in prostate cancer. Nature (2025). https://doi.org/10.1038/s41586-025-09727-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-025-09727-z